bioAffinity Technologies (BIAF) announced new appointments to its Medical and Scientific Advisory Board, including: David Ost; Daniel Sterman; and J. Scott Ferguson. The appointments reflect a planned expansion of the Company’s Medical and Scientific Advisory Board to ensure alignment with bioAffinity’s current clinical, scientific, and commercial priorities, including the ongoing integration of CyPath Lung into the standard of care for indeterminate pulmonary nodules.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF: